Participants are bracing for a bit more volatility than in past quarters.
This is a sign that portfolio managers are concerned about downside risks and paying a premium for portfolio protection.
It will probably see some interest due to the volatility and the new listing.
Since most of the open interest is in the may term, it is probably related to the drug study results later this month.
